Navigation Links
Randomized Study Comparing Cell Therapeutics' OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Date:8/18/2011

SEATTLE, Aug. 18, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC and MTA: CTIC) announced that enrollment has opened for a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX) and radiation ("RT") to the combination of temozolomide ("TMZ") and RT for patients with newly diagnosed glioblastoma, a high-grade malignant brain tumor.

The objectives of the study are to determine if OPAXIO and RT improve progression free survival ("PFS") and overall survival ("OS") compared to TMZ and RT as well as to evaluate neuro-cognitive function and toxicities of these therapies. If positive, results from the study could be used to plan a phase III study of OPAXIO added to standard radiation therapy for approval in this disease.

Glioblastoma is the most common and deadliest type of primary brain tumor in adults. It is estimated that 17,000 primary brain tumors are diagnosed each year in the U.S., 60% of which are gliomas with glioblastoma being the most prevalent. The prognosis for the great majority of patients with glioblastoma is poor with less than 25% of patients surviving two years with current therapies.

In a recent study, treatment with OPAXIO added to standard therapy with TMZ and RT resulted in a median PFS of 13.5 months in the subset of patients with GBS (n=17). Median OS has not yet been reached with 50% of patients having at least 22 months of follow-up since completing therapy. The study was presented in June 2011 by Drs. Suriya Jeyapalan, Heinrich Elinzano and Mark Goldman, Assistant Professors of Neurology and Neurosurgery, Brown University Oncology Group at the 2011 American Society of Clinical Oncology Annual Meeting. Additional survival data are expected to be presented at the Society of Neuro-Oncology annual meeting later this year.

"The data from the earlier OPAXIO study with an overal
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
3. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
4. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
5. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
10. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the ... Annual Meeting of Stockholders on May 4, 2015 (the ... the Annual Meeting represents a change of more than ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 On ... law H.R. 83, the Omnibus and Continuing Resolution ... time, made hydrocephalus a condition eligible to receive ... (CDMRP) administered by the Department of Defense (DoD). ... its allies on Capitol Hill, is celebrating this ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Coulter, Inc. (NYSE: BEC ), a leading ... and innovate complex biomedical testing, announced today it will ... at 5:00 p.m. ET to discuss the company,s third ... call, there will be a webcast presentation of accompanying ...
... 13 Osteotech, Inc. (Nasdaq: OSTE ), ... for regenerative healing, announced today that it has received ... Commission granted early termination of the Hart-Scott-Rodino waiting period ... of the merger remains subject to antitrust clearance in ...
... 13, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:Beckman Coulter to host Conference Call and Webcast Presentation for Third Quarter 2010 Earnings Results on October 27, 2010 2Osteotech Announces Early Termination of HSR Waiting Period 2Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 2Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 3Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 4Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 5Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 6Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 7Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 8
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... water pathogens may get a lot easier and cheaper thanks ... his team. , Syed Hashsham, an associate professor in ... for Microbial Ecology, is developing a portable, hand-held device capable ... water and food. , "This device will give ...
... failure and other health conditions, blood draws and diagnostic tests ... chemical or physiologic changes silently cause damage that is not ... future a tiny device, one the size of a nickel ... monitor and detect abnormalities, and could then relay data to ...
... the thymus, where the immune system's T cells develop, if ... thousands of proteins as "self." The research confirms an ... the immune system, and not only at the sites where ... of type 1 diabetes, or the joints in rheumatoid arthritis. ...
Cached Biology News:Professors to develop hand-held pathogen testing device 2Cardiologist's 'living chip' changes science of disease monitoring 2Cardiologist's 'living chip' changes science of disease monitoring 3Cardiologist's 'living chip' changes science of disease monitoring 4Proteins anchor memories in our brain 2Proteins anchor memories in our brain 3
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
PMA (YPMA-1)...
Biology Products: